O'Riordan W, Cardenas C, Shin E, et al. - For treatment of acute bacterial skin and skin structure infections (ABSSSI), researchers determined the efficacy and safety of once-daily oral omadacycline, an aminomethylcycline antibiotic, vs twice-daily oral linezolid via this phase 3, double-blind, randomized, non-inferiority study at 33 sites in the US. Between August 11, 2016 and June 6, 2017, they randomly assigned 735 participants (1:1) to receive either omadacycline (450 mg orally every 24 hours over the first 48 hours then 300 mg orally every 24 h) or linezolid (600 mg orally every 12 h) for 7–14 days. Outcomes suggest non-inferiority of once-daily oral omadacycline to twice-daily oral linezolid in adults with ABSSSI, with good safety and tolerability. Outcomes thereby support oral-only omadacycline as a novel treatment option for ABSSSI, with a possibility for a decrease in hospital admissions and cost savings.